title: Effect of erythromycin on myocardial repolarization in patients with community-acquired pneumonia.
abstract: BACKGROUND
  Erythromycin has been associated with prolongation of myocardial repolarization and torsades de pointes (TdP).
  
  
  METHODS
  To determine the frequency, dose-response, and risk factors for erythromycin-associated prolongation of myocardial repolarization, we observed data of patients admitted to our hospital with pneumonia who were treated with erythromycin.
  
  
  RESULTS
  In 35 women and 28 men enrolled in this study, the QTc increased from 434 +/- 4 milliseconds at baseline to 464 +/- 5 milliseconds after receiving a cumulative dose of 3.2 +/- 0.2 g of erythromycin. Neither age, sex, presence of preexistent congestive heart failure/coronary artery disease, electrolyte values, nor cumulative dose of erythromycin was associated with QTc prolongation. In 27 patients who received intravenous erythromycin for 3 days, the QTc increased from 427 +/- 5 milliseconds before to 461 +/- 8 milliseconds at 24 hours but did not increase further by day 3 (457 +/- 10 milliseconds). No patient in this cohort had TdP.
  
  
  CONCLUSIONS
  Erythromycin therapy is associated with prolongation of myocardial repolarization that manifests after the first few doses in a majority of patients.
authors.affiliation: Department of Internal Medicine, Bridgeport Hospital and Yale University School of Medicine, Conn., USA.
authors.forename: A
authors.initials: A
authors.lastname: Kdesh
authors.forename: C A
authors.initials: CA
authors.lastname: McPherson
authors.forename: Y
authors.initials: Y
authors.lastname: Yaylali
authors.forename: D
authors.initials: D
authors.lastname: Yasick
authors.forename: K
authors.initials: K
authors.lastname: Bradley
authors.forename: C A
authors.initials: CA
authors.lastname: Manthous
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000209:etiology; D016171:Torsades de Pointes / Q000139:chemically induced* / Q000503:physiopathology
chemical_list: D000900:Anti-Bacterial Agents; D004917:Erythromycin